Netupitant / Palonosetron Dosage

Medically reviewed by Drugs.com. Last updated on Jun 3, 2024.

Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced

Netupitant 300 mg-palonosetron 0.5 mg orally ONCE, given 60 minutes before chemotherapy on Day 1

ADDITIONAL MEDICATIONS:
Highly Emetogenic Cancer Chemotherapy, Including Cisplatin-Based Chemotherapy:

• Day 1: Dexamethasone 12 mg orally 30 minutes prior to chemotherapy
• Days 2 to 4: Dexamethasone 8 mg orally once a day

Anthracyclines and Cyclophosphamide-Based Chemotherapy and Chemotherapy Not Considered Highly Emetogenic:

• Day 1: Dexamethasone 12 mg orally 30 minutes prior to chemotherapy

Use: In combination with dexamethasone for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Renal Dose Adjustments

Mild to moderate renal dysfunction (CrCl 30 to 60 mL/min): No adjustment recommended.
Severe renal dysfunction (CrCl less than 30 mL/min) and end-stage renal disease: Not recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh score 5 to 8): No adjustment recommended.
Severe liver dysfunction (Child-Pugh score greater than 9): Not recommended.

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Administration advice:

• This drug can be taken without regard to food.

Storage requirements:

• Some experts recommend: Store in the original container

General:

• LIMITATION OF USE: This drug has not been studied for the prevention of nausea/vomiting associated with anthracycline PLUS cyclophosphamide chemotherapy.

Monitoring:

• HYPERSENSITIVITY: Hypersensitivity reactions
• NERVOUS SYSTEM: Signs/symptoms of serotonin syndrome

Patient advice:

• Patients should be advised to immediately report any signs/symptoms associated with serotonin syndrome or hypersensitivity reactions to their prescribers.
• Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
• Inform patients that this drug may cause dizziness, fatigue, and/or somnolence, and they should avoid driving or operating machinery if these side effects occur.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer